Clinical Trials
3 trialsNCT00303953 2014-05-12
PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00354185 2013-05-16
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00348985 2013-05-03
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
National Cancer Institute (NCI)
Phase 1 Completed